A20 protects cells from TNF-induced apoptosis through linear ubiquitin-dependent and -independent mechanisms.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
18 09 2019
Historique:
received: 22 07 2019
accepted: 29 08 2019
revised: 21 08 2019
entrez: 20 9 2019
pubmed: 20 9 2019
medline: 24 9 2020
Statut: epublish

Résumé

The cytokine TNF promotes inflammation either directly by activating the MAPK and NF-κB signaling pathways, or indirectly by triggering cell death. A20 is a potent anti-inflammatory molecule, and mutations in the gene encoding A20 are associated with a wide panel of inflammatory pathologies, both in human and in the mouse. Binding of TNF to TNFR1 triggers the NF-κB-dependent expression of A20 as part of a negative feedback mechanism preventing sustained NF-κB activation. Apart from acting as an NF-κB inhibitor, A20 is also well-known for its ability to counteract the cytotoxic potential of TNF. However, the mechanism by which A20 mediates this function and the exact cell death modality that it represses have remained incompletely understood. In the present study, we provide in vitro and in vivo evidences that deletion of A20 induces RIPK1 kinase-dependent and -independent apoptosis upon single TNF stimulation. We show that constitutively expressed A20 is recruited to TNFR1 signaling complex (Complex I) via its seventh zinc finger (ZF7) domain, in a cIAP1/2-dependent manner, within minutes after TNF sensing. We demonstrate that Complex I-recruited A20 protects cells from apoptosis by stabilizing the linear (M1) ubiquitin network associated to Complex I, a process independent of its E3 ubiquitin ligase and deubiquitylase (DUB) activities and which is counteracted by the DUB CYLD, both in vitro and in vivo. In absence of linear ubiquitylation, A20 is still recruited to Complex I via its ZF4 and ZF7 domains, but this time protects the cells from death by deploying its DUB activity. Together, our results therefore demonstrate two distinct molecular mechanisms by which constitutively expressed A20 protect cells from TNF-induced apoptosis.

Identifiants

pubmed: 31534131
doi: 10.1038/s41419-019-1937-y
pii: 10.1038/s41419-019-1937-y
pmc: PMC6751190
doi:

Substances chimiques

Receptors, Tumor Necrosis Factor, Type I 0
Ubiquitin 0
TNFAIP3 protein, human EC 3.4.19.12
Tumor Necrosis Factor alpha-Induced Protein 3 EC 3.4.19.12

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

692

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI052417
Pays : United States

Commentaires et corrections

Type : ErratumIn

Références

FEBS Lett. 2015 May 22;589(12):1369-75
pubmed: 25911380
Cell Rep. 2016 Mar 29;14(12):2846-58
pubmed: 26997266
PLoS One. 2011;6(9):e22356
pubmed: 21931591
Mol Cell. 2009 Dec 11;36(5):831-44
pubmed: 20005846
EMBO J. 2012 Oct 3;31(19):3856-70
pubmed: 23032187
J Exp Med. 2010 Jul 5;207(7):1513-23
pubmed: 20530205
Cell. 2009 Mar 20;136(6):1098-109
pubmed: 19303852
Nat Biotechnol. 2019 Feb;37(2):111-113
pubmed: 30718870
Nat Immunol. 2008 Mar;9(3):254-62
pubmed: 18246070
Cell Rep. 2016 Jun 14;15(11):2449-61
pubmed: 27264187
Methods Mol Biol. 2013;945:319-28
pubmed: 23097115
Nat Cell Biol. 2019 Jun;21(6):731-742
pubmed: 31086261
Arch Med Sci. 2014 Dec 22;10(6):1175-85
pubmed: 25624856
J Immunol. 2014 Aug 15;193(4):1539-1543
pubmed: 25015821
Biochem Pharmacol. 2010 Dec 15;80(12):2009-20
pubmed: 20599425
Mol Cell. 2004 Aug 27;15(4):535-48
pubmed: 15327770
EMBO J. 2009 Mar 4;28(5):513-22
pubmed: 19131965
J Immunol. 1995 Feb 15;154(4):1699-706
pubmed: 7836754
Nat Immunol. 2015 Jun;16(6):618-27
pubmed: 25939025
Mol Cell. 2010 Nov 24;40(4):548-57
pubmed: 21095585
Nature. 2015 Dec 17;528(7582):370-5
pubmed: 26649818
EMBO J. 2012 Oct 3;31(19):3845-55
pubmed: 23032186
Trends Immunol. 2016 Aug;37(8):535-545
pubmed: 27424290
Nat Commun. 2019 Apr 15;10(1):1729
pubmed: 30988283
Cell Death Differ. 2017 Jul;24(7):1172-1183
pubmed: 28362430
Cell. 2008 May 16;133(4):693-703
pubmed: 18485876
Nature. 2004 Aug 5;430(7000):694-9
pubmed: 15258597
J Mol Biol. 2008 Feb 15;376(2):526-40
pubmed: 18164316
Cell. 2018 Sep 6;174(6):1477-1491.e19
pubmed: 30146158
Immunity. 2013 May 23;38(5):896-905
pubmed: 23602765
Mol Cell Biol. 2004 Feb;24(4):1464-9
pubmed: 14749364
Mol Cell. 2015 Oct 1;60(1):63-76
pubmed: 26344099
Cell. 2009 May 15;137(4):721-35
pubmed: 19427028
Mol Cell. 2008 Jun 20;30(6):689-700
pubmed: 18570872
Nat Cell Biol. 2018 Dec;20(12):1389-1399
pubmed: 30420664
Trends Mol Med. 2018 Jan;24(1):49-65
pubmed: 29217118
Trends Immunol. 2014 Jan;35(1):22-31
pubmed: 24246475
Biochem Biophys Res Commun. 2016 Jun 3;474(3):452-461
pubmed: 27133719
EMBO Rep. 2014 Jul;15(7):775-83
pubmed: 24878851
Biochem J. 2011 Feb 15;434(1):93-104
pubmed: 21138416
Methods Mol Biol. 2018;1857:171-179
pubmed: 30136241
Biochem J. 2008 Jan 1;409(1):77-85
pubmed: 17961127
Biochem J. 2004 Mar 15;378(Pt 3):727-34
pubmed: 14748687
Nat Rev Immunol. 2012 Nov;12(11):774-85
pubmed: 23059429
Cell Death Differ. 2016 Jan;23(1):76-88
pubmed: 26024392
J Biol Chem. 1992 Jun 25;267(18):12424-7
pubmed: 1618749
Cell Rep. 2015 Dec 15;13(10):2258-72
pubmed: 26670046
J Biol Chem. 1996 Jul 26;271(30):18068-73
pubmed: 8663499
Cell Death Differ. 2013 Oct;20(10):1381-92
pubmed: 23892367

Auteurs

Dario Priem (D)

Center for Inflammation Research, VIB, Ghent, Belgium.
Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.

Michael Devos (M)

Center for Inflammation Research, VIB, Ghent, Belgium.
Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.

Sarah Druwé (S)

Center for Inflammation Research, VIB, Ghent, Belgium.
Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.

Arne Martens (A)

Center for Inflammation Research, VIB, Ghent, Belgium.
Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.

Karolina Slowicka (K)

Center for Inflammation Research, VIB, Ghent, Belgium.
Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.

Adrian T Ting (AT)

Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Manolis Pasparakis (M)

Institute for Genetics, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) and Center for Molecular Medicine, University of Cologne, Cologne, Germany.

Wim Declercq (W)

Center for Inflammation Research, VIB, Ghent, Belgium.
Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.

Peter Vandenabeele (P)

Center for Inflammation Research, VIB, Ghent, Belgium.
Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.

Geert van Loo (G)

Center for Inflammation Research, VIB, Ghent, Belgium.
Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.

Mathieu J M Bertrand (MJM)

Center for Inflammation Research, VIB, Ghent, Belgium. mathieu.bertrand@irc.vib-ugent.be.
Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium. mathieu.bertrand@irc.vib-ugent.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH